Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Chlodantane and P21 — mechanism, dosing, side effects, legal status, and pricing.
Chlodantane (ADK-910) is a non-peptide aryl-substituted 2-aminoadamantane amide, structurally related to bromantane and classified in Soviet pharmacological literature as an actoprotector/adaptogen. It has never been approved for human use in any jurisdiction and remains entirely unevaluated in clinical trials. All available data derive from animal and cell-culture experiments conducted in the former Soviet Union.
P21 (also P021) is a small peptidergic compound — the tetrapeptide core Asp-Gly-Gly-Leu with an N-terminal acetyl and a C-terminal adamantylated glycine amide (Ac-DGGL(A)G-NH2) — derived from an active region (residues ~148–151) of human ciliary neurotrophic factor (CNTF). It was designed and characterized in the Khalid Iqbal laboratory at the New York State Institute for Basic Research in Developmental Disabilities (NYS IBR). It is an experimental, preclinical compound — NOT FDA-approved and NOT tested in humans in published trials. Distinct from the cyclin-dependent kinase inhibitor protein p21/CDKN1A/WAF1 (a completely different gene product; the two share only the name).
Chlodantane
P21
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Chlodantane
No pricing data yet.
Check Chlodantane prices →P21
COA corpus from Disclosed Labs — independently tested batches only.
Chlodantane
1
COAs
99.9%
Avg purity
1
Labs
P21
2
COAs
99.1%
Avg purity
1
Labs
No human data exist; a 2012 review explicitly states that all pharmacological data derive from animal or cell-culture experiments, with no clinical research conducted. In unspecified animal models, chlodantane enhanced resistance to physical and toxic-chemical stressors, produced immunostimulating effects in stress-induced immunodeficiency, and protected against hypoxia, high and low ambient temperature, and toxic chemical challenge. Effects were reported to appear after a single administration, and immunostimulant activity was described as more pronounced than that of bromantane.
Evidence is preclinical (rodent) only. Key publication: Kazim, Blanchard, Dai, Tung, LaFerla, Iqbal & Iqbal, Neurobiology of Disease 2014 (PMID 25046994) reported that chronic oral P021 rescued cognition, boosted dentate-gyrus neurogenesis, and reduced tau hyperphosphorylation in 3xTg-AD mice. Additional preclinical papers from the Iqbal group (and collaborators) have shown dendritic/synaptic rescue in AD and aging rodent models (e.g., Kazim et al., Alzheimer's Res Ther 2017). No Phase 1/2/3 human trials have been published; no human safety or pharmacokinetic data exist. Grey-market vendor material is unvalidated — purity, identity, and dosing are not verifiable.
Chlodantane (Performance) and P21 (Cognitive) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs